$2.300
-0.242 (-10.51%)Zum Schluss
NERV im Vergleich zur Peergroup
In the context of the broader market, NERV competes directly with industry leaders such as PYPD and OTLK. With a market capitalization of $109.83M, it holds a significant position in the sector. When comparing efficiency, NERV's gross margin of N/A stands against PYPD's N/A and OTLK's -95.00%. Such benchmarking helps identify whether Minerva Neurosciences, Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Minerva Neurosciences Inc
Minerva reported a Q1 2026 net income of -$1,254,043,84, indicating ongoing financial struggles. The forward P/E ratio is 11.21, suggesting potential value if profitability improves. The current ratio is strong at 20.14, indicating good short-term liquidity.
Financials
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.